Summary & Overview
HCPCS S0132: Ganirelix Acetate 250 mcg Injection
HCPCS Level II code S0132 designates a 250 mcg injection of ganirelix acetate, a GnRH antagonist commonly used in assisted reproductive technology to prevent premature ovulation. Nationally, this code is relevant to fertility clinics, ambulatory infusion centers, and payers managing coverage for infertility treatments and associated medication administration. It matters for billing accuracy, benefit determinations, and tracking utilization of specialty fertility drugs.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of what S0132 represents clinically and operationally, plus guidance on typical sites of service. The publication outlines benchmarks and payer coverage considerations where available, summarizes relevant policy updates affecting coverage and billing for injectable fertility medications, and situates the code within clinical pathways for controlled ovarian stimulation. This piece is intended to inform billing professionals, revenue cycle staff, and policy analysts about the code’s role in fertility treatment billing and payer interactions.
Data not available in the input for some fields such as associated taxonomies, ICD-10 mappings, and detailed payer-specific coverage rules.
Billing Code Overview
HCPCS Level II code S0132 represents an injection of ganirelix acetate, 250 mcg. This code denotes a single administration of ganirelix acetate, a gonadotropin-releasing hormone (GnRH) antagonist used in assisted reproductive technology to prevent premature ovulation during controlled ovarian stimulation.
Service Type: Injection medication administration for fertility treatment.
Typical Site of Service: Infusion center, ambulatory clinic, or specialty reproductive medicine clinic where injectable fertility medications are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is a reproductive-age woman undergoing controlled ovarian stimulation as part of assisted reproductive technology (ART) such as in vitro fertilization (IVF). Ganirelix acetate 250 mcg is administered by subcutaneous injection to prevent premature luteinizing hormone (LH) surge and ovulation during the follicular phase. The clinical workflow includes baseline monitoring (transvaginal ultrasound and serum estradiol), initiation of gonadotropin injections, serial monitoring visits, and then daily or alternate-day administration of S0132 beginning when lead follicles reach the clinic’s size threshold (commonly 12–14 mm) until the day of ovulation trigger. Typical site of service is an outpatient fertility clinic, ambulatory surgery center if combined with egg retrieval, or physician office for teaching and dispensing the injection. The patient receives education on subcutaneous self-injection technique, observes injection during a clinic visit if needed, and returns for ongoing monitoring and the eventual oocyte retrieval procedure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no specific modifier applies and standard billing applies for the service |
22 |